The fallout for Venture Global Inc., in the wake of a troubled initial public offering, accelerated amid a market selloff ...

HistoSonics Inc., a medical device company whose backers include Johnson & Johnson’s venture capital arm, is weighing a US ...

By Arasu Kannagi Basil (Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to ...

Even so the deal solidifies Venture Global’s place in the public markets with an impressive $50 billion market cap. And it ...

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.

The IPO trend remains robust in 2025, driven by strong retail investor interest and a shift from FPIs to the primary market.

Learn about Karman Holdings' upcoming $100 million US IPO, their focus on missile and space systems, and the financial ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Dr Agarwal Healthcare IPO opens January 29 at ₹382-402 per share. GMP trends lower at ₹15, signaling a 4% premium. High OFS ...

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

Eyecare provider Dr Agarwal's Health Care Ltd.'s Rs 3,027.3-crore initial public offering is scheduled to open on Wednesday.

Rexpro Enterprises IPO shows a grey market premium of ₹10, indicating a potential listing price of ₹155. The IPO was ...